Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Within the section 3 DREAM3R research, first-line therapy with Imfinzi (durvalumab) plus chemotherapy demonstrated constant enhancements in total survival, progression-free survival, and...
The addition of two years of Xtandi (enzalutamide) to plain androgen deprivation remedy (ADT) and high-dose radiation remedy didn't considerably enhance metastasis-free...
Platinum-based chemotherapy plus Imfinzi (durvalumab), Avastin (bevacizumab), and Lynparza (olaparib) confirmed a statistically vital and clinically significant enchancment in median progression-free survival...
Ivonescimab mixed with chemotherapy considerably improved progression-free survival (PFS) in contrast with Tevimbra (tislelizumab-jsgr) plus chemotherapy in sufferers with superior squamous non–small...
